Shanghai Raas Revenue and Competitors
Estimated Revenue & Valuation
- Shanghai Raas's estimated annual revenue is currently $14.3M per year.
- Shanghai Raas's estimated revenue per employee is $251,000
Employee Data
- Shanghai Raas has 57 Employees.
- Shanghai Raas grew their employee count by -3% last year.
Shanghai Raas Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Shanghai Raas?
Shanghai Raas Blood Products is a medical device company based out of SHANGHAI. Shanghai Raas Blood Products representatives, don't miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees. Go here to get started: http://linkd.in/1DUpBvu
keywords:N/A
N/A
Total Funding
57
Number of Employees
$14.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Shanghai Raas News
... CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc.,...
Other companies that are preparing to reopen include biotechnology firm Shanghai Raas Blood Products and a unit of Shanghai Pharmaceuticals,...
LFB Group; Shanghai RAAS Blood Products; Jiangxi Boya Bio-Pharmaceutical; Hualan Biological Engineering; Harbin Pacific Biopharmaceutical; GREEN...
Other Companies in SHANGHAI
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 58 | -2% | N/A |
#2 | $7.4M | 59 | 59% | N/A |
#3 | $13.7M | 60 | 5% | N/A |
#4 | $318.4M | 61 | -5% | N/A |
#5 | $7.4M | 63 | -3% | N/A |